This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Journal: Journal of affective disorders 128(3):235-242 (2011)
Authors: M Isserles, O Rosenberg, P Dannon, Y Levkovitz, M Kotler, F Deutsch, B Lerer, A Zangen
Transcranial magnetic stimulation (TMS) enables non-surgical activation of specific brain areas. TMS over the prefrontal cortex (PFC) is emerging as a significant tool that can augment or replace non/partially effective antidepressant medications. Deep TMS (dTMS) utilizes newly developed coils that enable effective stimulation of deeper cortical layers involved in the pathophysiology of depression.
This study aimed to assess the H1-DTMS coil as an add-on to antidepressants in treating patients with major depression. We also intended to evaluate whether the antidepressant outcome of DTMS treatment is affected by a cognitive–emotional procedure performed during stimulation.
57 patients were enrolled in the study that included 4 weeks of daily 20 Hz stimulation sessions and additional 4 weekly sessions as a short maintenance phase. Two subgroups of patients received either positive or negative cognitive–emotional reactivation along with the stimulation sessions.
21 of 46 patients (46%) who received at least 10 stimulation sessions achieved response (improvement of≥50% in the Hamilton Depression Rating Scale (HDRS)) and 13 of them (28%) achieved remission (HDRS-24≤10) by the end of the daily treatment phase.Improvements were smaller in the negatively reactivated group and Beck Depression Inventory scores were not significantly improved in this group.
dTMS over the PFC proved to be safe and effective in augmenting anti depressant medications. Negative cognitive-emotional reactivation can disrupt the therapeutic effect of dTMS. A large sham controlled study is required to further establish the effectiveness of dTMS as an augmentation treatment and the role of cognitive reactivation during stimulation.